{
  "figure_1": "TSLP-induced CD4+\nT cell immunity transforms high-grade breast tumors into fibrocystic structures. (A) Time to tumor onset in K14-Tslptg, MMTV-PyMTtg (Tslp-PyMttg; n = 46) and PyMttg (n = 27) mice (log-rank test). (B) Number of palpable tumors in each Tslp-PyMttg (n = 28) and PyMttg (n = 20) mouse at 18–20 wk of age (Mann–Whitney U test). Bar graph shows mean + SD. (C) Sum of the volumes of all tumors in each Tslp-PyMttg (n = 28) and PyMttg (n = 20) mouse at 18–20 wk of age (Mann–Whitney U test). Bar graph shows mean + SD. (D) Percentage survival of Tslp-PyMttg (n = 46) and PyMttg (n = 27) mice (log-rank test). (E) Representative images of H&E-stained primary Tslp-PyMttg and PyMttg tumors at low (scale bar: 1 mm) and high (scale bar: 100 μm) magnifications, and the distribution of histological grades of Tslp-PyMttg (n = 29) and PyMttg (n = 18) breast tumors (Fisher’s exact test). (F) Representative images of CD3/CD4, CD3/CD8, MHCII/CD4, and CD103/CD4 immunofluorescence staining on Tslp-PyMttg and PyMttg tumors (scale bar: 100 μm). Inset in CD3/CD4 image shows a CD4+ T cell within the epithelial compartment of a differentiated Tslp-PyMttg breast tumor. Inset in MHCII/CD4 image highlights the interaction of CD4+ T cells with the APCs within Tslp-PyMttg tumor microenvironment. (G and H) Quantification of CD4+ T cells (G) and CD8+ T cells (H) in Tslp-PyMttg and PyMttg tumors. CD3/CD4 and CD3/CD8 double-positive cells counted in 10 HPF images in 11 tumor samples per group. HPF images for each sample were chosen randomly across the tumor section. Each dot represents one HPF image (unpaired t test). Bar graphs show mean + SD. (I) Time to tumor onset in Tslp-PyMttg Rag1KO + CD4+ T cells, PyMttg Rag1KO + CD4+ T cells, Tslp-PyMttg Rag1KO + CD8+ T cells, Tslp-PyMttg Rag1KO, and PyMttg Rag1KO T cells (P < 0.0001 for Tslp-PyMttg Rag1KO +CD4+ compared with PyMttg Rag1KO +CD4+ T cell; no statistical difference among the other groups [ns], log-rank test). (J) Number of palpable tumors at endpoint (≥18 wk old) in the five groups of mice (Mann–Whitney U test). Bar graph shows mean + SD. (K) Percentage survival in the five groups of animals (P < 0.0001 for Tslp-PyMttg Rag1KO + CD4+ compared with PyMttg Rag1KO + CD4+ T cell, no statistical difference among the other groups [ns]; log-rank test). (L) Distribution of histological grades of Tslp-PyMttg Rag1KO + CD4+ T cell tumors compared with all other groups combined (control groups, Fisher’s exact test). Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_2": "CD4+\nT cell immunity causes breast cancer terminal differentiation. (A) Representative images of TUNEL assay (upper panels) and immunofluorescence staining for Ki67 (lower panels) on Tslp-PyMttg and PyMttg tumors (scale bar: 100 μm). (B) Percentage Ki67+ cells in Tslp-PyMTtg (n = 9) and PyMTtg (n = 6) breast tumors. Quantifications were performed in 10 HPF images per tumor sample stained with Ki67. Each dot represents a tumor sample (Mann–Whitney U test). Bar graph shows mean + SD. (C) Scatter plot showing genes differentially regulated in Tslp-PyMttg Rag1KO + CD4+ T cell compared with PyMttg Rag1KO + CD4+ T cell. Dots highlighted in yellow and blue represent genes up- or down-regulated in Tslp-PyMttg Rag1KO + CD4+ T cell versus PyMttg Rag1KO + CD4+ T cell, respectively (n = 3 per group, false discovery rate ≤ 0.001 and log2 ratio ≥ 1). Genes of interest are indicated with their symbol or complete name. (D) Pathway enrichment analysis of genes associated with differential H3K27Ac mark in the tumors of Tslp-PyMttg Rag1KO + CD4+ T cell compared with PyMttg Rag1KO + CD4+ T cells (n = 2 per group). (E) Heatmap showing increased H3K27Ac mark in the enhancer region of genes associated with EMT in PyMttg Rag1KO + CD4+ T cell (control) compared with Tslp-PyMttg Rag1KO + CD4+ T cell (test) group. (F) Peaks of acetylation in the promoter regions (highlighted by black boxes) of representative EMT genes in Tslp-PyMttg Rag1KO + CD4+ T cells (red tracks) compared with PyMttg Rag1KO + CD4+ T cells (blue tracks). (G and H) Western blot for breast epithelial (MUC1, β-casein, and E-cadherin), mesenchymal (vimentin), and regulator of proliferation (p21) markers on tumor lysates from Tslp-PyMttg Rag1KO + CD4+ T cells, PyMttg Rag1KO + CD4+ T cells, and normal mammary gland (G) and Tslp-PyMttg, PyMttg, and normal mammary gland (H). GAPDH is used as the control housekeeping protein. (I) Quantification of protein bands in Tslp-PyMttg Rag1KO + CD4+ T cell and Tslp-PyMttg groups (test tumors) compared with PyMttg Rag1KO + CD4+ T cell and PyMttg groups (control tumors) and WT breast glands (Mann–Whitney U test). Bar graphs show mean + SD. Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_3": "CD4+\nT cells directly suppress breast epithelial cell proliferation. (A) Representative images of HC11 mammosphere immunofluorescence staining after exposure to supernatants derived from Tslp-PyMttg CD4+ T cells (test CD4+ T cell sup.), PyMttg TslprKO CD4+ T cells (control CD4+ T cell sup.), or cell culture medium (control medium). Equal total protein amounts of supernatants from second and third rounds of CD4+ T cell stimulation were used. Mammospheres were stained for E-cadherin (green), Ki67 (red), and DAPI (blue, scale bar: 100 μm). (B) Quantification of mammosphere size in test CD4+ T cell sup. (n = 20), control CD4+ T cell sup. (n = 40), and control medium (n = 30) conditions. Each dot represents one mammosphere (Mann–Whitney U test). Bar graph shows mean + SD. (C) Volcano plot showing significantly upregulated (red dots) and downregulated (green dots) genes in CD4+ T cells isolated from Tslp-PyMttg mice (test, n = 6) compared with CD4+ T cells isolated from PyMttg TslprKO mice (control, n = 4, log2 ratio > |1| and −log10 of posterior probability of equal expression [PPEE] >1.3 is considered significant). Genes of interest are indicated with their symbol. (D) Bar graph showing the top 12 secreted proteins detected in two Tslp-PyMttg CD4+ T cell (test) compared with two PyMttg TslprKO CD4+ T cell (control) supernatants determined using multiplexed quantitative mass spectrometry. Supernatants were from second and third rounds of CD4+ T cell stimulation. (E) Image of protein arrays performed on CD4+ T cell supernatants from test (first and third arrays) and control (second and last arrays). Supernatants used in this assay were collected after a first round of CD4+ T cell stimulation ex vivo (top two arrays) or after the second round of stimulation (bottom two arrays). Equal total protein amount of each supernatant was used in this assay. Red boxes highlight Th2-related cytokines differentially detected in test versus control samples. (F) Quantification of protein concentration, measured with ELISA, in test CD4+ T cell supernatants compared with control CD4+ T cell supernatants. Supernatants used in this assay were collected after T cell stimulation. Supernatants were from first and second rounds of CD4+ T cell stimulation (Mann–Whitney U test). Bar graph shows mean + SD. The same amount of total protein for each sample was used for protein detection and quantification in D, E, and F. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_4": "Th2 cell polarization mediates the immunity against breast carcinogenesis. (A–C) Comparison of tumor outcomes across Tslp-PyMttg Il4rKO, PyMttg Il4rKO, Tslp-PyMttg, and PyMttg mice including time to tumor onset (log-rank test; A), number of tumors per mouse over time (*, P < 0.005 comparing Tslp-PyMttg Il4rKO to Tslp-PyMttg and °, P < 0.05 comparing PyMttg Il4rKO to PyMttg, Mann–Whitney U test; B), and percentage survival of the animals in the four groups (log-rank test; C). (D) Distribution of histological grades of Tslp-PyMttg Il4rKO (n = 16), PyMttg Il4rKO (n = 20), Tslp-PyMttg (n = 20), and PyMttg (n = 13) tumors (Fisher’s exact test). (E) Tumor growth kinetic in Tslptg (test, n = 6, 6/6 tumors were <0.5 cm3 at the endpoint) versus WT (control, n = 10, 3/10 tumors were <0.5 cm3 at the endpoint) mice implanted with PyMttg primary breast tumors (two-way ANOVA). (F) Tumor growth kinetics in Tslptg (test, n = 7, 7/7 tumors were <0.5 cm3 at the endpoint) and WT (control, n = 5, 0/5 tumors were <0.5 cm3 at the endpoint) mice implanted with PyMttg Il4rKO primary breast tumors (two-way ANOVA). Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_5": "Antigen specificity of Th2 cell immunity against breast carcinogenesis. (A) Schematic diagram of the experimental paradigm used to elucidate the effector mechanism of TSLP-stimulated CD4+ T cells against breast cancer. Note that only transferred CD4+ T cells in the test groups express TSLP receptor (Tslpr), but all other cells including the implanted tumor cells lack TSLP receptor (i.e., TslprKO). (B) Spider plot of PyMttg TslprKO primary breast tumor growth in Tslptg TslprKO mice injected with WT (test, n = 10, 6/10 tumors were <0.5 cm3 at the endpoint) versus TslprKO (control, n = 10, 4/10 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (two-way ANOVA). (C) Spider plot of PyMtOvatg TslprKO primary tumor growth in Tslptg TslprKO mice injected with WT (n = 10, 9/10 tumors were <0.5 cm3 at the endpoint) versus TslprKO (n = 10, 2/10 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (two-way ANOVA). (D) Survival rate of Tslptg TslprKO mice injected with WT (n = 15) versus TslprKO (n = 19) CD4+ T cells followed by PyMtOvatg TslprKO primary tumor implantation (log-rank test). (E) Distribution of histological grades of PyMtOvatg TslprKO primary tumors developed in Tslptg TslprKO mice injected with WT (n = 15) versus TslprKO (n = 20) CD4+ T cells (Fisher’s exact test). (F) Representative images of H&E-stained PyMtOvatg TslprKO breast tumors from (top to bottom): tumor donor, Tslptg TslprKO mouse injected with WT CD4+ T cells, and mouse injected with TslprKO CD4+ T cell. Note the degree of breast tumor differentiation in WT (test) group compared with the original tumor harvested from the donor mouse and TslprKO (control) group. (G) Representative images of CD3/CD4, CD3/CD8, MHCII/CD4, and CD103/CD4 immunofluorescence staining on PyMtOvatg TslprKO primary tumors developed in Tslptg TslprKO mice injected with WT versus TslprKO CD4+ T cells. Note that CD103 colocalizes with CD4 and CD3 on few cells in the WT tumors (scale bars, 100 μm). (H and I) Representative flow plots showing percentage GATA3+ Th2 and Foxp3+ regulatory T cells (Tregs) in PyMtOvatg TslprKO breast tumors of Tslptg TslprKO mice injected with CD45.1+ WT versus TslprKO CD4+ T cells (H) and percentage GATA3+ and Ki67+ cells among tumor-infiltrating Foxp3− CD4+ T effector cells in Tslptg TslprKO mice injected with WT or TslprKO CD4+ T cells (I). Injected CD45.1+ WT CD4+ T cells are highlighted in red; TslprKO CD4+ T cells are in blue. Numbers on the plots represent the percentage of cells within each gate. (J and K) Percentage GATA3+ Th2 cells among CD45.1+ WT CD4+ T cells (test, n = 6) versus TslprKO CD4+ T cells (control, n = 10; J) and Ki67+ cells among CD45.1+ WT Foxp3− CD4+ T cells (test, n = 10) versus TslprKO Foxp3− CD4+ T cells (control, n = 10; K) isolated from PyMtOvatg TslprKO breast tumors developed in Tslptg TslprKO mice (Mann-Whitney U test). Bar graphs show mean + SD. (L) H&E and immunofluorescence images show breast tumor and adjacent mammary gland of a Tslptg TslprKO mouse injected with WT CD4+ T cells and implanted with PyMtOvatg TslprKO tumor. CD4 immunofluorescence staining highlights CD4+ T cells infiltrating the tumor, but not the adjacent normal mammary gland of the mouse (insets: scale bars, 100 μm). (M) Representative images of immunohistochemical staining for OVA in breast tumor and adjacent mammary gland of Tslptg TslprKO mice implanted with high-grade PyMtOvatg TslprKO tumor. Note that CD4+ Th2 cell immunity suppressed an OVA-expressing tumor by transforming it to gland-like structures while sparing the OVA-negative adjacent mammary glands (scale bar: 100 μm). (N) Representative images of H&E-stained skin, lung, and mammary glands of Tslptg TslprKO mice injected with WT versus TslprKO CD4+ T cells and implanted with PyMtOvatg TslprKO tumor. No sign of inflammation is detected in the nontumor tissues at the endpoint (scale bar: 100 μm). (O) Spider plot showing PyMtOvatg TslprKO primary tumor growth in Tslptg TslprKO mice injected with OTII (n = 9, 7/9 tumors were <0.5 cm3 at the endpoint) versus TslprKO (n = 10, 2/10 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (two-way ANOVA). (P) Representative images of H&E-stained PyMtOvatg TslprKO breast tumors from (top to bottom): tumor donor, tumor recipient mice injected with OTII, or TslprKO CD4+ T cells (scale bar: 100 μm). (Q) Spider plot of PyMttg TslprKO primary tumor growth in Tslptg TslprKO mice injected with Ova-specific CD4+ T cells (OTII, n = 7, 3/7 tumors were <0.5 cm3 at the endpoint) versus TslprKO CD4+ T cells (n = 8, 3/8 tumors were <0.5 cm3 at the endpoint, two-way ANOVA). (R) Representative images of H&E-stained PyMttg TslprKO breast tumors from (top to bottom): tumor donor mouse, mouse injected with OTII CD4+ T cells, and mouse injected with TslprKO CD4+ T cells (scale bar: 100 μm). Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_6": "IL-3, IL-5, and GM-CSF cytokines mediate Th2 cell immunity against breast carcinogenesis. (A–C) Spider plots of PyMtOvatg TslprKO primary tumor growth in Tslptg TslprKO mice injected with Il4KO (n = 8, 2/8 tumors were <0.5 cm3 at the endpoint; A), TnfKO (n = 6, 2/6 tumors were <0.5 cm3 at the endpoint; B), IfngKO (n = 10, 6/10 tumors were <0.5 cm3 at the endpoint; C) mutant CD4+ T cells compared to TslprKO CD4+ T cells (n = 8, 3/8 tumors were <0.5 cm3; n = 5, 0/5 tumors were <0.5 cm3; and n = 8, 2/8 tumors were <0.5 cm3 at the endpoint, respectively; two-way ANOVA). (D and E) Spider plots of primary PyMtOvatg TslprKO tumor growth in Tslptg TslprKO mice injected with Il3KO (n = 6, 4/6 tumors were <0.5 cm3 at the endpoint) versus TslprKO (n = 7, 2/7 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (two-way ANOVA; D) and WT (n = 9, 6/9 tumors were <0.5 cm3 at the endpoint) versus TslprKO (n = 8, 1/8 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (E) while both groups were treated with anti–IL-5 plus anti–GM-CSF blocking antibodies (ab; two-way ANOVA). (F) Spider plot of PyMtOvatg TslprKO primary tumor growth in Tslptg TslprKO mice injected with Il3KO CD4+ T cells in combination with anti–IL-5/GM-CSF antibodies (n = 13, 1/13 tumors were <0.5 cm3 at the endpoint) versus TslprKO CD4+ T cells and rat IgG isotype control antibody (n = 14, 1/14 tumors were <0.5 cm3 at the endpoint; two-way ANOVA). (G) Schematic diagram of the experimental paradigm used to elucidate the role of IL-3/IL-5/GM-CSF receptors on breast cancer cells in mediating the antitumor effects of TSLP-stimulated CD4+ T cells against breast cancer. (H) Spider plot of PyMtOvatg Csf2rbKO Csf2rb2KO primary tumor growth in Tslptg TslprKO mice injected with WT (n = 7, 1/7 tumors were <0.5 cm3 at the endpoint) versus TslprKO CD4+ T cells (n = 7, 1/7 tumors were <0.5 cm3 at the endpoint, two-way ANOVA). (I) PyMtOvatg Csf2rbKO Csf2rb2KO tumor weights at the endpoint in Tslptg TslprKO mice injected with WT (n = 7) versus TslprKO (n = 7) CD4+ T cells (Mann-Whitney U test). (J) Percentage survival of Tslptg TslprKO mice injected with WT (n = 7) versus TslprKO (n = 7) CD4+ T cells followed by PyMtOvatg Csf2rbKO Csf2rb2KO primary tumor implantation (log-rank test). (K) Distribution of histological grades of PyMtOvatg Csf2rbKO Csf2rb2KO primary tumors developed in Tslptg TslprKO mice injected with WT (n = 7) versus TslprKO (n = 7) CD4+ T cells (Fisher’s exact test). (L) Representative images of H&E-stained PyMtOvatg Csf2rbKO Csf2rb2KO breast tumors from Tslptg TslprKO mouse injected with WT CD4+ T cells, Tslptg TslprKO mouse injected with TslprKO CD4+ T cells, and the donor tumor from PyMtOvatg Csf2rbKO Csf2rb2KO mouse (scale bar: 100 μm). (M) Representative flow plots of transcription factor expression in PyMtOvatg Csf2rbKO Csf2rb2KO breast tumor–infiltrating CD4+ T cells isolated from Tslptg TslprKO mice injected with CD45.1+ WT versus TSLPRKO CD4+ T cells. Numbers on the plots represent the percentage of cells within each gate. (N) Percentage of GATA3+ Th2 cells among CD45.1+ WT CD4+ T cells (test, n = 6) versus TslprKO CD4+ T cells (control, n = 6) isolated from PyMtOvatg Csf2rbKO Csf2rb2KO breast tumors in Tslptg TslprKO mice (Mann–Whitney U test). Bar graph shows mean + SD. Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_7": "Transient induction of TSLP provides lasting immunity against breast cancer. (A) Schematic diagram of the experimental procedure used to test the effect of transient topical TSLP induction on Th2 cell immunity against primary breast tumor growth. (B and C) TslprKO mice received WT or TslprKO CD4+ T cells, PyMtOvatg TslprKO breast tumor, and topical calcipotriol treatment. Tumor growth kinetics (two-way ANOVA; B) and survival rate (log-rank test; C) of TslprKO mice injected with WT (n = 7, 4/7 tumors were <0.5 cm3 at the endpoint) versus TslprKO (n = 8, 0/8 tumors were <0.5 cm3 at the endpoint) CD4+ T cells. The duration of treatment is indicated by purple bars on the graphs. (D) Schematic diagram of the experimental paradigm used to elucidate the efficacy of calcipotriol treatment for the suppression of established breast tumor. Note that the calcipotriol treatment was started when implanted tumors became palpable (∼5 mm in diameter) and was repeated every 3 d for 4 wk. Transferred WT CD4+ T cells express CD45.1. (E) Spider plot of PyMtOvatg TslprKO primary tumor growth in TslprKO mice injected with WT (n = 6, 3/6 tumors were <0.5 cm3 at the endpoint) versus TslprKO (n = 6, 0/6 tumors were <0.5 cm3 at the endpoint) CD4+ T cells and treated with calcipotriol (two-way ANOVA). The duration of calcipotriol treatment is indicated by purple bar on the graph. (F) Survival rate of TslprKO mice injected with WT (n = 6) versus TslprKO (n = 6) CD4+ T cells followed by PyMtOvatg TslprKO primary tumor implantation and calcipotriol treatment (log-rank test). The duration of calcipotriol treatment is indicated by purple bar on the graph. (G) Distribution of histological grades of PyMtOvatg TslprKO primary tumors developed in TslprKO mice injected with WT (n = 6) versus TslprKO (n = 6) CD4+ T cells and treated with calcipotriol (Fisher’s exact test). (H) Representative images of H&E-stained PyMtOvatg TslprKO breast tumors at low (scale bar: 1 mm) and high (scale bar: 100 μm) magnifications from TslprKO mouse injected with WT CD4+ T cells and treated with calcipotriol, TslprKO mouse injected with TslprKO CD4+ T cell and treated with calcipotriol, and the donor tumor from PyMtOvatg TslprKO mouse (scale bar: 100 μm). (I) Representative flow plots of transcriptional factor expression in CD4+ T cells isolated from PyMtOvatg TslprKO breast tumor from TslprKO mice injected with CD45.1+ WT versus TSLPRKO CD4+ T cells and treated with calcipotriol. Numbers on the plots represent the percentage of cells within each gate. (J and K) Percentage GATA3+ Th2 cells (J) and Foxp3+ regulatory T cells (Tregs; K) among CD45.1+ WT CD4+ T cells (test, n = 7) versus TslprKO CD4+ T cells (control, n = 6) isolated from PyMtOvatg TslprKO breast tumors and their draining lymph nodes in TslprKO mice treated with calcipotriol (Mann–Whitney U test). Bar graph shows mean + SD. Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_8": "Endogenous and induced TSLP activate Th2 immunity against primary cancer development. (A–C) PyMttg TslprKO, PyMttg, and Tslp-PyMttg mice on C57BL/6 background are compared for time to tumor onset (log-rank test; A), number of tumors per mouse (unpaired t test; B), and percentage survival (log-rank test; C). Bar graph shows mean + SD. (D) Representative images of H&E-stained PyMttg TslprKO, PyMttg, and Tslp-PyMttg. Note the glandular (i.e., differentiated) nature of the breast tumor in Tslp-PyMttg group (scale bar: 100 μm). (E) TSLP protein levels per mg of total tissue protein measured with ELISA in WT mammary glands (n = 12), PyMttg breast tumor (n = 12), and Tslp-PyMttg breast tumor (n = 12, Mann–Whitney U test). Bar graph shows mean + SD. (F) Schematic diagram of the experimental paradigm used to examine the impact of topical calcipotriol-induced CD4+ T cell immunity against Brca1-defcient primary breast tumors. (G) Spider plot showing K14-Cre Brca1f/f p53f/f TslprKO breast tumor growth in Rag1KO mice injected with WT (test, n = 9, 9/9 tumors were <0.5 cm3 at the endpoint) versus TslprKO (control, n = 9, 4/9 tumors were <0.5 cm3 at the endpoint) CD4+ T cells (two-way ANOVA). (H) Representative flow plots of transcriptional factor expression in the tumor-infiltrating CD4+ T cells isolated from Rag1KO mice injected with WT versus TSLPRKO CD4+ T cells. Numbers on the plots represent the percentage cells within each gate. (I) Spider plot of Her2tg primary breast tumor growth in Tslptg (n = 6, 6/6 tumors were <0.5 cm3) versus WT (n = 8, 3/8 tumors were <0.5 cm3 at the endpoint) mice (two-way ANOVA). (J) Representative flow plots of transcription factor expression in the Her2tg tumor-infiltrating CD4+ T cells isolated from Tslptg and WT mice. Histograms showing percentage Ki67+ Foxp3− CD4+ T effector cells isolated from Tslptg and WT mice. Numbers on the plots represent the percentage of cells within each gate. (K) Representative images of H&E-stained Her2tg breast tumors developed in Tslptg versus WT mice (scale bar: 100 μm). (L) Histogram showing expression levels of mouse IL-3Rα (CD123) and the common β chain receptor (CD131) on the surface of EpCAM+ CD45− P48-Cre LSL-KrasG12D p53f/f pancreatic tumor cells. Gray histograms with dashed outline show FMO control. (M) Schematic diagram of the experimental paradigm used to elucidate the effect of WT CD4+ T cells and the impact of IL-3/IL-5/GM-CSF blockade on pancreatic tumor growth in response to TSLP induction. Note that the transferred WT CD4+ T cells express CD45.1. (N) Graph of P48-Cre LSL-KrasG12D p53f/f primary tumor growth in Tslptg TslprKO mice injected with WT (n = 8), Il3KO (n = 7), or TslprKO (n = 8) CD4+ T cells. Mice that received Il3KO CD4+ T cells were treated with IL-5 and GM-CSF blocking antibodies, while mice that received WT and TslprKO CD4+ T cells were treated with control antibody (two-way ANOVA). Each of the tumors in the studies is from a separate mouse. All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.",
  "figure_9": "Loss of TSLP expression in human breast cancer cells is associated with cancer progression and worse survival outcomes. (A) Immunofluorescence staining for TSLP in human breast tissue at three stages of cancer development. Note the complete loss of TSLP in invasive carcinoma (scale bar: 100 μm). (B) Box plot of TSLP expression in normal mammary glands versus breast cancers across TCGA/GTEx datasets (one-way ANOVA, Gene Expression Profiling Interactive Analysis database). TPM, transcript count per million. (C)\nTSLP RNA in situ hybridization showing TSLP expression in the breast cancer (upper panel) compared with its matched adjacent normal tissue (lower panel). Note that the normal mammary epithelial cells are the dominant source of TSLP transcripts in the breast (scale bar: 100 μm). (D) Normalized TSLP protein levels measured with ELISA in the paired samples of breast cancer and adjacent normal breast tissue from 28 patients with primary breast cancer (Wilcoxon test). (E) Overall survival of patients with basal-like, luminal A, luminal B, and HER2 breast cancers divided based on high (top 30%, n = 234) and low (bottom 30%, n = 234) tumor TSLP expression levels in TCGA (log-rank test, Gene Expression Profiling Interactive Analysis database). (F) Disease-free survival of patients with basal-like, luminal A, luminal B, and HER2 breast cancers divided based on high (top 30%, n = 234) and low (bottom 30%, n = 234) tumor TSLP expression levels in TCGA (log-rank test, Gene Expression Profiling Interactive Analysis database). All experimental data verified in at least two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.0001."
}